Shares of Eli Lilly (NYSE: LLY) were plunging 14.8% as of 11:14 a.m. ET on Thursday. The big drugmaker reported results for ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

GLP-1's, which are traditionally diabetes medications, have exploded in popularity since they were approved for weight-loss.

A slew or company results were causing big market moves ahead of the opening bell Thursday, and for many, earnings-beat wasn’t enough to prevent a selloff.

Eli Lilly stock crashes as late-stage data for weight-loss pill falls short of expectations. Analyst explains why data wasn't ...

The main indexes finished well off their session highs after a disappointing batch of corporate earnings reports.

U.S. stocks are drifting lower after President Donald Trump’s latest tariffs took effect on dozens of countries, but the moves are modest and stocks rose in much of the rest ...

The iPhone maker's shares [rallied for a second day]( ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...